Physician profile
Bridgette A Christopher
NPI 1790044238
$4,625.44
in general payments reported to CMS, 2019-2025
30 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $187 · 2021: $224 · 2022: $820 · 2023: $1,122 · 2024: $1,224 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $850.36 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $676.04 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $528.04 | 2019-2025 | |
| Medtronic, INC. | $373.60 | 2021-2023 | Reveal Linq |
| Astrazeneca Pharmaceuticals LP | $331.93 | 2019-2024 | Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $327.10 | 2021-2025 | |
| Irhythm Technologies, INC. | $247.20 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $202.93 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.32 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $157.08 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.84 | 2019-2022 | |
| Esperion Therapeutics, INC. | $98.58 | 2023-2025 | Nexletol |
| Pfizer INC. | $80.10 | 2019-2025 | |
| Scpharmaceuticals INC. | $61.15 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $56.32 | 2023 | Inpefa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $53.88 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $47.15 | 2023-2025 | Optimizer, Optimizer |
| Merck Sharp & Dohme LLC | $32.83 | 2025 | Verquvo |
| Lundbeck LLC | $29.11 | 2020 | |
| Abiomed | $26.98 | 2024 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $23.62 | 2024 | Arcalyst |
| Boston Scientific Corporation | $23.55 | 2024 | Watchman Access System |
| Portola Pharmaceuticals, LLC | $23.35 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.35 | 2025 | Onpattro |
| Lilly USA, LLC | $15.00 | 2024 | Zepbound |
| Cvrx, INC. | $14.32 | 2022 | |
| Heartflow, INC. | $13.36 | 2024 | |
| Abbott Laboratories | $13.35 | 2023 | Cardiomems |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgette Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.